Applications of visual evoked potentials and Fourier-domain optical coherence tomography in Parkinson's disease: a controlled study.

PURPOSE The goal of this cross-sectional observational study was to quantify the pattern-shift visual evoked potentials (VEP) and the thickness as well as the volume of retinal layers using optical coherence tomography (OCT) across a cohort of Parkinson's disease (PD) patients and age-matched controls. METHODS Forty-three PD patients and 38 controls were enrolled. All participants underwent a detailed neurological and ophthalmologic evaluation. Idiopathic PD cases were included. Cases with glaucoma or increased intra-ocular pressure were excluded. Patients were assessed by VEP and high-resolution Fourier-domain OCT, which quantified the inner and outer thicknesses of the retinal layers. VEP latencies and the thicknesses of the retinal layers were the main outcome measures. RESULTS The mean age, with standard deviation (SD), of the PD patients and controls were 63.1 (7.5) and 62.4 (7.2) years, respectively. The patients were predominantly in the initial Hoehn-Yahr (HY) disease stages (34.8% in stage 1 or 1.5, and 55.8 % in stage 2). The VEP latencies and the thicknesses as well as the volumes of the retinal inner and outer layers of the groups were similar. A negative correlation between the retinal thickness and the age was noted in both groups. The thickness of the retinal nerve fibre layer (RNFL) was 102.7 μm in PD patients vs. 104.2 μm in controls. CONCLUSIONS The thicknesses of retinal layers, VEP, and RNFL of PD patients were similar to those of the controls. Despite the use of a representative cohort of PD patients and high-resolution OCT in this study, further studies are required to establish the validity of using OCT and VEP measurements as the anatomic and functional biomarkers for the evaluation of retinal and visual pathways in PD patients.

[1]  R. Inzelberg,et al.  Retinal nerve fiber layer thinning in Parkinson disease , 2004, Vision Research.

[2]  G. Fénelon,et al.  Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. , 2000, Brain : a journal of neurology.

[3]  A. Antal,et al.  Primary Visual and Visuocognitive Deficits , 2013 .

[4]  J. Kassubek,et al.  Retinal single-layer analysis in Parkinsonian syndromes: an optical coherence tomography study , 2013, Journal of Neural Transmission.

[5]  U. Mosimann,et al.  Retinal thickness in Parkinson's disease. , 2011, Parkinsonism & related disorders.

[6]  I. Bodis-Wollner,et al.  Inner retinal layer thinning in Parkinson disease. , 2009, Archives of ophthalmology.

[7]  A. Schnitzler,et al.  Optical Coherence Tomography in Parkinsonian Syndromes , 2012, PloS one.

[8]  M. Repka,et al.  Ocular motor and sensory function in Parkinson's disease. , 2012, Ophthalmology.

[9]  Lees Aj,et al.  Parkinson's Disease Society Brain Bank, London: overview and research. , 1993 .

[10]  H. Kolb,et al.  The synaptic organization of the dopaminergic amacrine cell in the cat retina , 1990, Journal of neurocytology.

[11]  M. Yahr,et al.  Measurements of visual evoked potentials in Parkinson's disease. , 1978, Brain : a journal of neurology.

[12]  A. Antal,et al.  Visuo-cognitive dysfunctions in Parkinson's disease. , 1998, Clinical neuroscience.

[13]  I. Bodis-Wollner Visual deficits related to dopamine deficiency in experimental animals and Parkinson's disease patients , 1990, Trends in Neurosciences.

[14]  D Regan,et al.  Low-contrast letter charts in early diabetic retinopathy, ocular hypertension, glaucoma, and Parkinson's disease. , 1984, The British journal of ophthalmology.

[15]  A. Lang,et al.  Phenotype in parkinsonian and nonparkinsonian LRRK2 G2019S mutation carriers , 2011, Neurology.

[16]  T. Di Paolo,et al.  Decreased dopamine in the retinas of patients with Parkinson's disease. , 1990, Investigative ophthalmology & visual science.

[17]  Hansjürgen Bratzke,et al.  Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages) , 2002, Journal of Neurology.

[18]  Y. Çağlar,et al.  Correlation between retinal morphological and functional findings and clinical severity in Parkinson’s disease , 2008, Documenta Ophthalmologica.

[19]  A. Lees,et al.  Parkinson's Disease Society Brain Bank, London: overview and research. , 1993, Journal of neural transmission. Supplementum.

[20]  A. Mariani,et al.  Amacrine cells of the rhesus monkey retina , 1990, The Journal of comparative neurology.

[21]  C. Tranchant Parkinson's disease and nonmotor dysfunction , 2006 .

[22]  C. Nicholson,et al.  Extracellular dopamine concentration in the retina of the clawed frog, Xenopus laevis. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[23]  M. Ghilardi,et al.  Visual evoked potentials in parkinsonism and dopamine blockade reveal a stimulus-dependent dopamine function in humans. , 1986, Journal of neurology, neurosurgery, and psychiatry.

[24]  O. Blin,et al.  Dopaminergic modulation of visual sensitivity in man , 1993, Fundamental & clinical pharmacology.

[25]  M. Moschos,et al.  Morphologic Changes and Functional Retinal Impairment in Patients with Parkinson Disease without Visual Loss , 2011, European journal of ophthalmology.

[26]  A. Lang,et al.  Parkinson's disease. First of two parts. , 1998, The New England journal of medicine.